In Vitro Efficacies and Resistance Profiles of Rifampin-Based Combination Regimens for Biofilm-Embedded Methicillin-Resistant Staphylococcus aureus
Author(s) -
Hung-Jen Tang,
Chi-Chung Chen,
Kuo-Chen Cheng,
Kuan-Ying Wu,
Yi-Chung Lin,
Chun-Cheng Zhang,
TzuChieh Weng,
WenLiang Yu,
YuHsin Chiu,
Han Siong Toh,
Shyh-Ren Chiang,
Bo Su,
WenChien Ko,
Yin-Ching Chuang
Publication year - 2013
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01236-13
Subject(s) - tigecycline , fusidic acid , linezolid , fosfomycin , microbiology and biotechnology , daptomycin , teicoplanin , minocycline , biofilm , methicillin resistant staphylococcus aureus , staphylococcus aureus , vancomycin , antibiotics , biology , medicine , bacteria , genetics
To compare thein vitro antibacterial efficacies and resistance profiles of rifampin-based combinations against methicillin-resistantStaphylococcus aureus (MRSA) in a biofilm model, the antibacterial activities of vancomycin, teicoplanin, daptomycin, minocycline, linezolid, fusidic acid, fosfomycin, and tigecycline alone or in combination with rifampin against biofilm-embedded MRSA were measured. The rifampin-resistant mutation frequencies were evaluated. Of the rifampin-based combinations, rifampin enhances the antibacterial activities of and even synergizes with fusidic acid, tigecycline, and, to a lesser extent, linezolid, fosfomycin, and minocycline against biofilm-embedded MRSA. Such combinations with weaker rifampin resistance induction activities may provide a therapeutic advantage in MRSA biofilm-related infections.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom